Kalender
| Est. tid* | ||
| 2027-02-17 | 08:30 | Bokslutskommuniké 2026 |
| 2026-11-18 | 08:30 | Kvartalsrapport 2026-Q3 |
| 2026-08-19 | 08:30 | Kvartalsrapport 2026-Q2 |
| 2026-05-20 | 08:30 | Kvartalsrapport 2026-Q1 |
| 2026-02-18 | 08:30 | Bokslutskommuniké 2025 |
| 2025-12-02 | - | Extra Bolagsstämma 2025 |
| 2025-11-19 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-21 | - | Kvartalsrapport 2025-Q1 |
| 2025-05-09 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2025-04-08 | - | Årsstämma |
| 2025-02-19 | - | Bokslutskommuniké 2024 |
| 2024-11-20 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-05 | - | Årsstämma |
| 2024-05-23 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2024-05-22 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-04 | - | Extra Bolagsstämma 2023 |
| 2024-02-21 | - | Bokslutskommuniké 2023 |
| 2023-11-22 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-30 | - | Årsstämma |
| 2023-05-31 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-25 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-12-23 | - | Extra Bolagsstämma 2022 |
| 2022-11-16 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-17 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-19 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2022-05-18 | - | Årsstämma |
| 2022-05-18 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-11-10 | - | Kvartalsrapport 2021-Q3 |
| 2021-11-03 | - | Extra Bolagsstämma 2021 |
| 2021-08-11 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-23 | - | Årsstämma |
| 2021-05-20 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-11-11 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-12 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-29 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2020-06-26 | - | Årsstämma |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-20 | - | Bokslutskommuniké 2019 |
| 2019-11-13 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-14 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-27 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2019-05-24 | - | Årsstämma |
| 2019-05-24 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-21 | - | Bokslutskommuniké 2018 |
| 2018-11-07 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-15 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2018-05-16 | - | Årsstämma |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
| 2017-11-15 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-16 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-18 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2017-05-17 | - | Årsstämma |
| 2017-05-17 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-15 | - | Bokslutskommuniké 2016 |
| 2016-10-27 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-29 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Enorama Pharma AB (publ) ("Enorama Pharma" or the "Company") announces today that the board of directors has decided to prepare a balance sheet for liquidation purposes. The decision has been made due to the fact that the Company's subsidiary Enorama Pharma Inc. (the "Subsidiary") has received a decision on Refuse-to-File from the U.S. Food and Drug Administration, as previously announced by Enorama Pharma on 2 February 2026. The decision entails that the assets related to the Subsidiary may need to be revalued. The board of directors therefore considers that there is reason to believe that the Company's equity is less than half of the registered share capital.
The balance sheet for liquidation purposes shall be reviewed by the Company's auditor, Ernst & Young AB, and as soon as this review is completed, the auditor will announce the outcome to the Company. If the balance sheet for liquidation purposes shows that the equity is less than half of the registered share capital, the board of directors will convene an initial general meeting for liquidation purposes in accordance with the Companies Act. The general meeting may then resolve to continue the Company's operations, in which case the board of directors shall prepare a new balance sheet for liquidation purposes, and the Company shall hold a new general meeting, within eight months from the date of the first general meeting for liquidation purposes. During this period, the equity shall be restored.
The work to secure the Company's financing continues.
CONTACT
Enorama Pharma AB (publ)
Bengt Jönsson, acting CEO
[email protected]
Strandvägen 7A, 114 51 Stockholm.
www.enorama.se
Enorama Pharma AB is listed on Nasdaq First North Growth Market.
The company's Certified Adviser is Tapper Partners AB, +46 (0)70 44 010 98, [email protected].
ABOUT ENORAMA PHARMA
Enorama Pharma's vision is to be a leading global producer and supplier of consumer-friendly, oral nicotine products. The company intends to expand through product and brand development and by establishing strategically important collaborations. For more information, visit www.enorama.se.
This disclosure contains information that Enorama Pharma is obliged to make public pursuant to the EU Market Abuse Regulation (EU No 596/2014). The information was submitted for publication, through the agency of the contact person, on 13 February 2026 at 11:45 CET.